Aziyo Biologics and LeMaitre Vascular Partner for the Distribution of Aziyo’s Cardiovascular Portfolio
21 April 2023 - 6:30AM
Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that
develops and commercializes biologic products to improve
compatibility between medical devices and the patients who need
them, today announced it has entered into a distribution agreement
with LeMaitre Vascular, Inc. (Nasdaq: LMAT) (“LeMaitre”), a
provider of vascular devices, implants and services. Under the
agreement terms, Aziyo will grant LeMaitre exclusive U.S.
distribution rights for the products within its cardiovascular
segment: ProxiCor® PC, ProxiCor® CTR, Tyke® and VasCure®.
“We are thrilled to collaborate with LeMaitre,
an established leader in the vascular space, to distribute our
cardiovascular surgery products,” said Dr. Randy Mills, President
and Chief Executive Officer of Aziyo. “Our products are designed to
be highly efficacious across a wide range of applications, and we
look forward to expanding their availability by leveraging
LeMaitre’s much larger commercial organization. This partnership
should increase our operational efficiency as we focus our
commercial resources behind our CanGaroo Envelope, which is
utilized to help reduce complications associated with implantable
electronic devices such as pacemakers, defibrillators and
neuromodulation devices.”
Aziyo’s cardiovascular products are based on an
extracellular matrix derived from porcine small intestine
submucosa, which has been shown to modulate biologic healing
response and reduce inflammation in a range of surgical
applications. The products include: Proxicor® PC, used for
pericardial closure; ProxiCor® CTR, used for cardiac tissue repair;
Tyke®, the only extracellular matrix cleared for neonatal and
infant patch, pledget and intracardiac repair; and VasCure® for
vascular repair. The term of the collaboration is three years, and
LeMaitre will have the exclusive option to acquire the product line
following the first year or under certain other circumstances.
David Roberts, LeMaitre’s President, commented,
“We are pleased to be partnering with Aziyo to add these
next-generation products to our U.S. product offering and to
provide our vascular and cardiac surgeons an extracellular option
in addition to our existing range of biologic patches.”
About Aziyo Biologics
Aziyo develops and commercializes biologic
products to improve compatibility between medical devices and the
patients who need them. With a growing population in need of
implantable technologies, Aziyo’s mission is to humanize medical
devices to improve patient outcomes. For more information, visit
www.Aziyo.com.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements can be identified
by words such as “projects,” “may,” “will,” “could,” “would,”
“should,” “believes,” “expects,” “anticipates,” “estimates,”
“intends,” “plans,” “potential,” “promise” or similar references to
future periods. All statements contained in this press release that
do not relate to matters of historical fact should be considered
forward-looking statements, including statements and information
concerning the effectiveness of our products, the ability to expand
availability of our products or increase our operational efficiency
as a result of our distribution arrangement with LeMaitre, and the
potential success of our distribution arrangement with LeMaitre.
Forward-looking statements are based on management’s current
assumptions and expectations of future events and trends, which
affect or may affect our business, strategy, operations or
financial performance, and actual results may differ materially
from those expressed or implied in such statements due to numerous
risks and uncertainties. Forward-looking statements are inherently
subject to risks and uncertainties, some of which cannot be
predicted or quantified, and other important factors that may cause
actual results, performance or achievements to differ materially
from those contemplated or implied in this press release,
including, but not limited to, risks regarding the ability to
successfully execute or realize the anticipated benefits under our
distribution arrangement with LeMaitre; our inability to generate
sufficient revenue to achieve or sustain profitability; adverse
changes in economic conditions and instability and disruption of
credit markets; our ability to continue as a going concern; our
products and our ability to enhance, expand, develop and
commercialize its product offerings; the impact on our business of
the recall of a single lot of our FiberCel product and the
discontinuation of its sales by our distribution partner; our
dependence on our commercial partners; physician awareness of the
distinctive characteristics, and acceptance by the medical
community, of our products; the ability to obtain regulatory
approval or other marketing authorizations; and our intellectual
property rights, and other important factors which can be found in
the “Risk Factors” section of Aziyo’s public filings with the
Securities and Exchange Commission (“SEC”), including Aziyo’s
Annual Report on Form 10-K for the year ended December 31, 2022, as
such factors may be updated from time to time in Aziyo’s other
filings with the SEC, including, Aziyo’s Quarterly Reports on Form
10-Q, accessible on the SEC’s website at www.sec.gov and the
Investor Relations page of Aziyo’s website at
https://investors.aziyo.com. Because forward-looking statements are
inherently subject to risks and uncertainties, you should not rely
on these forward-looking statements as predictions of future
events. Any forward-looking statement made by Aziyo in this press
release is based only on information currently available and speaks
only as of the date on which it is made. Except as required by
applicable law, Aziyo expressly disclaims any obligations to
publicly update any forward-looking statements, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Investors:Matt SteinbergFINN
Partnersmatt.steinberg@finnpartners.com
Media:Courtney GuyerAziyo Biologics,
Inc.PR@aziyo.com
Aziyo Biologics (NASDAQ:AZYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aziyo Biologics (NASDAQ:AZYO)
Historical Stock Chart
From Apr 2023 to Apr 2024